Unit:
Speciality Breast DiseasesLibrary of the School of Health Sciences
Author:
Papachatzopoulou Eftychia
Supervisors info:
Δημητρακάκης Κωνσταντίνος, Καθηγητής, Ιατρική Σχολή ΕΚΠΑ
Αρκαδόπουλος Νικόλαος, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Μιχαλόπουλος Νικόλαος, Αναπληρωτής Καθηγητης, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Σύγκριση κλασσικών κλινικοπαθολογικών στοιχείων με τα αποτελέσματα της γονιδιακής υπογραφής Mammaprint Blueprint
Translated title:
Comparison between the classical histologic characteristics and the results of mammaprint-blueprint.
Summary:
INTRODUCTION: Breast cancer is the most common type of cancer among women. It is essential to identify correctly the molecular type of cancer, since it defines the therapeutic plan. The molecular type of cancer, is usually identified by methods of classic immunohistochemistry (IHC) and Fluorescence in situ hybridization (FISH), which classifies the cancer into 4 categories Luminal A, Luminal B, HER2 and triple negative cancer. However, during the past decades the molecular signatures and especially Mammaprint/Blueprint offer the possibility of a more accurate molecular stratification, examining 80 genes on the tumor.
OBJECTIVES-METHODS: We enrolled 60 patients who came in our clinic with an early-stage breast cancer and were treated initially with surgical removal of the tumor (ongectomy/mastectomy) and sentinel node biopsy. Then the tumor was sent for molecular evaluation with Mammaprint/Blueprint. We compared the results from classic IHC and Mammaprint/Blueprint with SPSS.
RESULTS:The results from Mammaprint/Blueprint were in accordance with IHC in 61% (37) patients, while 38% (23) of the patient were reclassified by Mammaprint/Blueprint. From the 36 patients who had Luminal A cancers according to the IHC, 12 (33% of Luminal A) were found Luminal B by Mammaprint/Blueprint and 1 (2.7% of Luminal A) was HER2. From the 24 cancers who were Luminal B according to the IHC, 10 patients (41.6% of Luminal B) were reclassified by Mammaprint/Blueprint as Luminal A.
CONCLUSIONS-DISCUSSION: The molecular signature Mammaprint/Blueprint can reclassify patients with breast cancer, which has a huge clinical significance since it defines the further therapies that should follow.
Main subject category:
Health Sciences
Keywords:
Breast cancer, Mammaprint-blueprint, Immunohistochemistry
Number of references:
282
